#USA #New York #Class Action #Sarepta Therapeutics #ELEVIDYS

Class Action Notification for Sarepta Therapeutics Investors

On August 4, 2025, The Gross Law Firm announced an urgent notice for shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) regarding a potential class action lawsuit. This notice is particularly important for individuals who purchased shares of Sarepta during the designated class period between June 22, 2023, and June 24, 2025.

Key Details of the Lawsuit

The allegations within the complaint are serious, suggesting that Sarepta Therapeutics issued misleading statements regarding its gene therapy product, ELEVIDYS. It is claimed that the company:
1. Did not adequately disclose the significant safety risks associated with ELEVIDYS, a prescription gene therapy aimed at treating Duchenne muscular dystrophy.
2. Failed to implement effective trial protocols that could detect severe side effects from the therapy, raising questions about patient safety.
3. Experienced a need to halt recruitment and dosing during ELEVIDYS trials due to the severity of adverse events, which has since attracted regulatory scrutiny and increased the risk associated with the therapy's approval status.
4. Misled investors with overly optimistic statements lacking a reasonable basis.

These allegations could significantly impact the perceptions of Sarepta’s stock and financial health, placing shareholders at risk for losses.

Important Deadlines

The deadline for shareholders to register for participation in this class action is August 25, 2025. It is vital for affected shareholders to act promptly, as registering will not only allow them to partake in potential recovery but also keep them informed about the process through updates via a portfolio monitoring system.

How to Register

To ensure your participation, you can register your information through the following link: Sarepta Loss Submission Form. There is no cost or obligation to participate, making it essential to act swiftly to secure your rights.

The Firm Behind the Action

The Gross Law Firm is a nationally recognized legal entity specializing in class-action lawsuits, dedicated to safeguarding the financial interests of shareholders impacted by deceptive or fraudulent corporate behavior. The firm's mission is to advocate for responsible business practices and accountability among large corporations.

By joining this lawsuit, investors can take a significant step toward recovering losses incurred from potentially misleading information provided by Sarepta Therapeutics. As the firm emphasizes, past results do not guarantee similar future outcomes, but they remain committed to fighting on behalf of investors.

If you are a shareholder in Sarepta Therapeutics and believe you may have been affected by these issues, do not hesitate. Register your claim now to protect your financial investments and stay informed about developments in the case. For more information, you can contact The Gross Law Firm directly at their New York office:

Contact Details
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Don't miss your chance to participate in this class action. Make sure your rights are protected and stand up against corporate misconduct that can affect your investments.